首页> 外文期刊>International journal of applied mechanics >Adoptive Cell Therapy-Harnessing Antigen-Specific T cells to Target Solid Tumours
【24h】

Adoptive Cell Therapy-Harnessing Antigen-Specific T cells to Target Solid Tumours

机译:采用细胞治疗利用抗原特异性T细胞靶向实体瘤

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years, much research has been focused on the field of adoptive cell therapies (ACT) that use native or genetically modified T cells as therapeutic tools. Immunotherapy with T cells expressing chimeric antigen receptors (CARs) demonstrated great success in the treatment of haematologic malignancies, whereas adoptive transfer of autologous tumour infiltrating lymphocytes (TILs) proved to be highly effective in metastatic melanoma. These encouraging results initiated many studies where ACT was tested as a treatment for various solid tumours. In this review, we provide an overview of the challenges of T cell-based immunotherapies of solid tumours. We describe alternative approaches for choosing the most efficient T cells for cancer treatment in terms of their tumour-specificity and phenotype. Finally, we present strategies for improvement of anti-tumour potential of T cells, including combination therapies.
机译:近年来,许多研究一直专注于使用本土或转基因T细胞作为治疗工具的收养细胞疗法(ACT)领域。 具有表达嵌合抗原受体(汽车)的T细胞的免疫疗法在治疗血液学恶性肿瘤的治疗方面表现出巨大的成功,而通过在转移性黑色素瘤中被证明是高效的自体肿瘤浸润淋巴细胞(TILS)的巨大转移。 这些令人鼓舞的结果启动了许多研究,即在各种实体肿瘤的治疗中测试了该法。 在本综述中,我们概述了基于T细胞的实体肿瘤免疫治疗的挑战。 我们描述了在其肿瘤特异性和表型方面选择癌症治疗最有效的T细胞的替代方法。 最后,我们提出了改善T细胞的抗肿瘤潜力的策略,包括组合疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号